Overexpression of NPRL2 in NPRL2-deficient and cisplatin-resistant NSCLC cells reactivated cellular response to cisplatin treatment and promoted tumor suppression activity in vitro and in mouse models [20]. Here, NPRL2 is linked to non-small cell lung carcinoma.